Emerging in Diabetic Cardiomyopathy: Molecular Pathways and Targets for Therapeutic Intervention

Area of Science:

• Cardiology
• Molecular Biology
• Pharmacology

Background:

• Diabetic cardiomyopathy (DCM) is a significant complication of diabetes, lacking effective prevention and treatment strategies.
• Current therapies for DCM are limited, necessitating novel approaches.
• Understanding the molecular mechanisms underlying DCM is crucial for developing new interventions.

Purpose of the Study:

• To review emerging molecular targets for the pathological hallmarks of diabetic cardiomyopathy.
• To explore novel RNA-based therapeutic strategies for managing DCM.
• To discuss the potential of these targets in drug discovery for DCM.

Main Methods:

• Comprehensive literature review of research on molecular targets and RNA therapeutics for DCM.
• Analysis of pathways involved in DCM, including fibrosis, inflammation, apoptosis (PANoptosis, cuproptosis, ferroptosis), and mitochondrial dysfunction.
• Identification and discussion of specific molecular targets such as PDE4D, LGR6, IFI16, GDF11, TFEB, SFRP1, FGF21, TGR5, NR4A3, EZH2, piR112710, and TUG1.

Main Results:

• Several molecular targets show promise in inhibiting DCM hallmarks like cardiomyocyte fibrosis and modulating inflammatory and apoptotic pathways.
• Specific targets like Phosphodiesterase 4D (PDE4D) and Transcription factor EB (TFEB) are highlighted for their potential therapeutic roles.
• RNA-based therapeutics, including piR112710 and TUG1, offer alternative strategies for combating DCM progression.

Conclusions:

• Novel molecular targets and RNA-based therapeutics present a promising avenue for future diabetic cardiomyopathy drug discovery.
• Targeting pathways such as PANoptosis, cuproptosis, ferroptosis, and mitochondrial dysfunction could lead to effective DCM interventions.
• Further research into these targets is essential for developing breakthrough treatments for diabetic cardiomyopathy.